HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.

AbstractBACKGROUND & AIMS:
Chemotherapy modestly prolongs survival of patients with advanced gastric cancer, but strategies are needed to increase its efficacy. Histone deacetylase (HDAC) inhibitors modify chromatin and can block cancer cell proliferation and promote apoptosis.
METHODS:
Gastric cancer cell lines were incubated with the HDAC inhibitor LBH589 (Panobinostat, Novartis, Germany); levels of proliferation, apoptosis, histone acetylation, and gene expression were determined. We identified factors downstream of HDAC that regulated chemoresistance. The effects of combination chemotherapy of HDAC inhibitors and anthracyclines were studied in CEA424/SV40 T-antigen (CEA/Tag) transgenic mice, which develop gastric tumors. We analyzed gastric tumor samples from patients using immunohistochemistry.
RESULTS:
HDAC2 was expressed in human gastric cancer cell lines and tumor samples, as well as in gastric tumors from CEA/Tag mice, compared with non-neoplastic gastric tissue. LBH589 inhibited proliferation of cancer cells in vitro. LBH589 down-regulated expression of genes that mediate anthracycline resistance by activating expression of Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain 2 (CITED2), a gene that mediates sensitivity to chemotherapeutics. Pre-incubation of cells with an HDAC inhibitor and overexpression of CITED2-sensitized gastric cell lines to anthracycline-mediated cell death. In CEA/Tag mice, LBH589 induced tumor-cell expression of CITED2 and increased the efficacy of anthracycline to reduce tumor growth. Levels of CITED2 were increased in gastric tumor samples from patients who had complete responses to epirubicin.
CONCLUSIONS:
The HDAC inhibitor LBH589 can overcome the resistance of mouse gastric cancer cells to anthracyclines by inducing expression of CITED2. Levels of CITED2 in gastric tumors correlate with patients' response to epirubicin. LBH589 might be used to increase the response of patients to anthracyclines.
AuthorsIvonne Regel, Lisa Merkl, Teresa Friedrich, Elke Burgermeister, Wolfgang Zimmermann, Henrik Einwächter, Ken Herrmann, Rupert Langer, Christoph Röcken, Ralf Hofheinz, Roland Schmid, Matthias P Ebert
JournalGastroenterology (Gastroenterology) Vol. 143 Issue 1 Pg. 99-109.e10 (Jul 2012) ISSN: 1528-0012 [Electronic] United States
PMID22465428 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Anthracyclines
  • Antibiotics, Antineoplastic
  • CITED2 protein, human
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Repressor Proteins
  • Trans-Activators
  • Epirubicin
  • Panobinostat
Topics
  • Animals
  • Anthracyclines (pharmacology)
  • Antibiotics, Antineoplastic (pharmacology)
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Epirubicin (pharmacology)
  • Gene Expression
  • Histone Deacetylase Inhibitors (pharmacology)
  • Humans
  • Hydroxamic Acids (pharmacology)
  • Indoles
  • Mice
  • Mice, Transgenic
  • Panobinostat
  • Repressor Proteins (genetics)
  • Stomach Neoplasms (drug therapy, genetics)
  • Trans-Activators (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: